Table 1.
Patients baseline characteristics (n = 50).
| Patient Characteristic | Value |
|---|---|
| Median age, years (range) | 49 (37–68) |
| Sex | |
| Male | 26 (52.0%) |
| Female | 24 (48.0%) |
| ECOG performance status | |
| 0–1 | 33 (66.0%) |
| 2 | 17 (34.0%) |
| Primary cancer Site | |
| Left colon | 26 (52.0%) |
| Right colon | 12 (24.0%) |
| Rectum | 12 (24.0%) |
| Histology | |
| Adenocarcinoma | 48 (96.0%) |
| Mucinous carcinoma | 1 (2.0%) |
| Undifferentiated carcinoma | 1 (2.0%) |
| Metastatic Site | |
| Liver | 33 (66.0%) |
| Lung | 25 (50.0%) |
| Abdominal lymph node | 8 (16.0%) |
| Peritoneum | 16 (32.0%) |
| Other | 15 (30.0%) |
| No. of metastatic sites | |
| ≤2 | 17 (34.0%) |
| >2 | 33 (66.0%) |
| KRAS Status | |
| Wild type | 23 (46.0%) |
| Mutated | 27 (54.0%) |
| BRAF mutation | |
| No | 48 (96.0%) |
| Yes | 2 (4.0%) |
| Prior targeted treatments | |
| Neither | 15 (30.0%) |
| Bevacizumab and Cetuximab | 5 (10.0%) |
| Bevacizumab only | 25 (50.0%) |
| Cetuximab only | 5 (10.0%) |
ECOG, Eastern Cooperative Oncology Group.